Metsigletic

Metformin Hydrochloride, the active ingredient in Metsigletic, is a Biguanide presented as a tablet for oral use. It is combined with Sitagliptin, a DPP‑4 inhibitor, to treat type 2 diabetes mellitus in adult patients requiring improved glycaemic control. It is indicated for patients who have not achieved target HbA1c with monotherapy.

GNH USA supplies Metsigletic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides full regulatory documentation to support importers and healthcare providers.

Metsigletic, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control when added to diet, exercise and other antidiabetic agents. - Inadequate response to metformin alone: provides additional HbA1c reduction for patients not reaching targets on metformin monotherapy. - Combination therapy simplification: merges two complementary mechanisms into a single oral tablet, reducing pill burden.

Metsigletic may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Headache. - Decreased appetite.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening condition, especially in patients with renal impairment. - Severe hypoglycaemia: particularly when combined with sulfonylureas or insulin. - Acute pancreatitis: sudden onset abdominal pain with elevated enzymes. - Allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or hepatitis.

Before initiating Metsigletic, clinicians should consider several safety aspects.

- Renal function: assess eGFR and monitor periodically; avoid in severe renal impairment. - Hepatic function: contraindicated in patients with significant liver disease. - Lactic acidosis risk: avoid in conditions predisposing to hypoxia or metabolic acidosis. - Pregnancy and lactation: use only if potential benefit justifies the potential risk to the fetus or infant. - Drug interactions: review concomitant medications for agents that may affect metformin or sitagliptin levels. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Metsigletic can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): increased risk of metformin accumulation and lactic acidosis. - Potent CYP2C8 inhibitors (e.g., gemfibrozil): may raise metformin plasma concentrations. - Concurrent sulfonylureas or insulin: heightened risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Alcohol consumption: can potentiate metformin‑related lactic acidosis. - Iodinated contrast agents: temporary discontinuation of metformin is recommended before and after imaging. - Diuretics (e.g., thiazides): may affect renal clearance of metformin, requiring dose adjustment. - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function and electrolytes.